Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1.23% is 89% above its 5-year average of -11.57%, around the middle of its 5-year range (-179.33%–91.69%).
189.05% below its 12-month average of 1.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 3.26%.
EBITDA MARGIN
-1.23%
EBITDA MARGIN AVG TTM
1.38%
EBITDA MARGIN AVG 3Y
-8.47%
EBITDA MARGIN AVG 5Y
-11.57%
EBITDA MARGIN AVG 10Y
-13.22%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-189.05%
CURRENT VS 3Y AVG
+85.48%
CURRENT VS 5Y AVG
+89.37%
CURRENT VS 10Y AVG
+90.70%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$3.44B
EBITDA Margin
10.88%
TTM Avg
18.32%
3Y Avg
-3.89%
5Y Avg
-19.05%
Market Cap
$3.16B
EBITDA Margin
-54.45%
TTM Avg
-179.51%
3Y Avg
-231.98%
5Y Avg
-287.87%
Market Cap
$3.15B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
Market Cap
$3.09B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$4.21B
EBITDA Margin
-250.61%
TTM Avg
-502.94%
3Y Avg
-374.26%
5Y Avg
-228.13%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CareDx, Inc (CDNA) | $3.61B | -1.23% | 1.38% | -8.47% | -11.57% |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 10.88% | 18.32% | -3.89% | -19.05% |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -54.45% | -179.51% | -231.98% | -287.87% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -359.19% | -174.35% | -417.41% | -1450.57% |
| AbCellera Biologics Inc. (ABCL)vs › | $4.21B | -250.61% | -502.94% | -374.26% | -228.13% |
| Edgewise Therapeutics, Inc. (EWTX)vs › | $4.34B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | 89.92% | 49.57% | 44.47% | 4968.54% |
Gross Margin
70.6%
EBITDA Margin
-1.2%
Operating Margin
-0.9%
Net Margin
24.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 3.26% |
| 2026-03-31 | 6.05% |
| 2025-12-31 | -0.72% |
| 2025-09-30 | 4.91% |
| 2025-06-30 | -6.60% |
| 2025-03-31 | -3.63% |
| 2024-12-31 | 91.69% |
| 2024-09-30 | -6.76% |
| 2024-06-30 | -2.57% |
| 2024-03-31 | -19.59% |
| 2023-12-31 | -179.33% |
| 2023-09-30 | -35.35% |
| 2023-06-30 | -32.21% |
| 2023-03-31 | -25.32% |
| 2022-12-31 | -17.75% |
| 2022-09-30 | -16.40% |
| 2022-06-30 | -22.41% |
| 2022-03-31 | -19.54% |
| 2021-12-31 | -15.15% |
| 2021-09-30 | -7.55% |
| 2021-06-30 | -2.56% |
| 2021-03-31 | 2.62% |
| 2020-12-31 | -0.80% |
| 2020-09-30 | -0.87% |
| 2020-06-30 | -20.40% |
| 2020-03-31 | -9.17% |
| 2019-12-31 | -10.78% |
| 2019-09-30 | -12.89% |
| 2019-06-30 | -18.43% |
| 2019-03-31 | -14.87% |
| 2018-12-31 | -5.27% |
| 2018-09-30 | -8.05% |
| 2018-06-30 | -23.69% |
| 2018-03-31 | -29.86% |
| 2017-12-31 | -26.14% |
| 2017-09-30 | -24.16% |
| 2017-06-30 | -22.51% |
| 2017-03-31 | -65.69% |
| 2016-12-31 | -167.00% |
| 2016-09-30 | -30.74% |
| 2016-06-30 | -56.15% |
| 2016-03-31 | -96.13% |
| 2015-12-31 | -63.79% |
| 2015-09-30 | -41.62% |
| 2015-06-30 | -37.78% |
| 2015-03-31 | -16.99% |
| 2014-12-31 | 7.38% |
| 2014-09-30 | 22.92% |
| 2014-06-30 | -3.38% |
| 2014-03-31 | -2.04% |
| 2013-12-31 | 10.79% |
| 2013-09-30 | -3.57% |
| 2013-06-30 | -1.69% |
| 2013-03-31 | -10.58% |
